These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19192640)

  • 1. Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens.
    Igawa S; Takahashi T; Nakamura Y; Tsuya A; Ono A; Shukuya T; Murakami H; Endo M; Yamamoto N
    Anticancer Res; 2008; 28(6B):3855-8. PubMed ID: 19192640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer.
    Igawa S; Sasaki J; Ishihara M; Otani S; Maki S; Hiyoshi Y; Kasajima M; Katono K; Takakura A; Masuda N
    Chemotherapy; 2013; 59(2):99-105. PubMed ID: 24021914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
    Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
    Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
    Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
    J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
    Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
    J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].
    Nitta T; Yamasaki M; Kajihara T; Mito A; Awaya H; Ikegami Y; Arita K
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1045-9. PubMed ID: 20567105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: a retrospective study.
    Kim JH; Kim HS; Kwon JH; Park S; Kim HY; Jung JY; Kim HJ; Song HH; Lee GW; Lee SI; Gong SJ; Lee JA; Kim KJ; Zang DY
    Lung Cancer; 2009 Mar; 63(3):405-9. PubMed ID: 18621432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
    Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
    Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
    Kaneda H; Okamoto I; Hayashi H; Yoshioka H; Miyazaki M; Kudoh S; Kimura T; Sugiura T; Sawa T; Takeda K; Iwamoto Y; Satouchi M; Akita K; Saito H; Goto I; Shibata K; Fukuoka M; Nakagawa K;
    J Thorac Oncol; 2010 Jan; 5(1):105-9. PubMed ID: 19884859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term amrubicin chemotherapy for small-cell lung cancer.
    Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Kawase I
    Anticancer Res; 2012 Apr; 32(4):1423-7. PubMed ID: 22493380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.
    Yoshida H; Sekine I; Tsuta K; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
    Jpn J Clin Oncol; 2011 Jul; 41(7):897-901. PubMed ID: 21636606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Our clinical experiences of amrubicin hydrochloride monotherapy in extensive-disease small cell lung cancer].
    Kawakami M; Ohno S; Tsujita A; Hosono T; Kobayashi A; Yamasawa H; Bando M; Sugiyama Y
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):273-6. PubMed ID: 18281764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
    Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
    Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis comparing the safety and efficacy of chemotherapy in elderly and non-elderly non-small-cell lung cancer patients.
    Tsubata Y; Honda T; Okimoto T; Miura K; Karino F; Iwamoto S; Suzuki T; Hamaguchi S; Kanda H; Sutani A; Kuraki T; Isobe T
    Geriatr Gerontol Int; 2012 Jul; 12(3):499-505. PubMed ID: 22233257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer.
    Totani Y; Saito Y; Hayashi M; Tada T; Kohashi Y; Mieno Y; Kato A; Imizu H; Yoneda Y; Hoshino T; Uchiyama Y; Takeuchi Y; Okazawa M; Sakakibara H
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1181-5. PubMed ID: 19377885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.